Factors affecting prognosis and need for anti-vascular endothelial growth factor injections in wet age-related macular degeneration

被引:0
|
作者
Kizilay, Muhammet Emin [1 ]
Sengun, Goezde Derin [1 ]
Esen, Fehim [1 ]
Durmus, Ebubekir [1 ]
Oguz, Halit [1 ]
Aykut, Veysel [1 ,2 ]
机构
[1] Istanbul Medeniyet Univ, Fac Med, Dept Ophthalmol, Istanbul, Turkiye
[2] Istanbul Medeniyet Univ, Goztepe Prof Dr Suleyman Yalcin City Hosp, Dept Ophthalmol, Istanbul, Turkiye
关键词
Age related macular degeneration; Vascular endothelial growth factor; Micronutrition; Hormone replacement therapy; HORMONE REPLACEMENT THERAPY; DOUBLE-ORGAN BIAS; ANTI-VEGF AGENTS; FELLOW EYES; REPRODUCTIVE FACTORS; CONTROLLED-TRIALS; VITAMIN-C; RANIBIZUMAB; BEVACIZUMAB; ESTROGEN;
D O I
10.1007/s10792-024-03243-1
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PurposeTo understand factors affecting visual prognosis and the number of intravitreal antivascular endothelial growth factor (anti-VEGF) injections needed to stabilize wet age-related macular degeneration (AMD).MethodsIn this retrospective cohort, 119 treatment-na & iuml;ve wet AMD patients were followed for two years. In patients with bilateral disease, the eye with worse best-corrected visual acuity (BCVA) or that received more intravitreal injections was recruited as the study eye. In all visits, BCVA was recorded, ophthalmological examination was performed including macular optical coherence tomography imaging. Twenty health status/lifestyle questions were asked to the patients via phone as potential risk factors. All patients received 3 loading doses of intravitreal bevacizumab injections and received repeat injections of aflibercept or ranibizumab when the eye had a new, active neovascular lesion.ResultsPatients who took regular micronutrition had similar visual outcome and injection numbers compared to the ones who did not. Patients with bilateral disease needed less intravitreal injections compared to unilateral AMD patients (p = 0.016) and women on hormone replacement therapy (HRT) required less injections compared to the women who were not (p = 0.024). Female patients had a mean gain of 2.7 letters while male patients lost 3.8 letters (p = 0.038). Wet AMD started at an earlier age in smokers (p = 0.002). Patients with a better education level presented earlier with better BCVA (p = 0.037).ConclusionHRT and anti-VEGF injections to the fellow eye improved the prognosis of wet AMD, while male patients had slightly worse prognosis. Estrogen's protective effects and potential contribution in wet AMD needs further attention.Retrospectively registered: 2020/0622.ConclusionHRT and anti-VEGF injections to the fellow eye improved the prognosis of wet AMD, while male patients had slightly worse prognosis. Estrogen's protective effects and potential contribution in wet AMD needs further attention.Retrospectively registered: 2020/0622.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Radiotherapy for anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration
    Ying, Gui-shuang
    Vanderbeek, Brian L.
    LANCET, 2024, 404 (10447): : 4 - 5
  • [2] Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration
    Ip, Michael S.
    Scott, Ingrid U.
    Brown, Gary C.
    Brown, Melissa M.
    Ho, Allen C.
    Huang, Suber S.
    Recchia, Franco M.
    OPHTHALMOLOGY, 2008, 115 (10) : 1837 - 1846
  • [3] Anti-vascular endothelial growth factor for neovascular age-related macular degeneration
    Solomon, Sharon D.
    Lindsley, Kristina
    Vedula, Satyanarayana S.
    Krzystolik, Magdalena G.
    Hawkins, Barbara S.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (08):
  • [4] Anti-vascular endothelial growth factor for neovascular age-related macular degeneration
    Solomon, Sharon D.
    Lindsley, Kristina
    Vedula, Satyanarayana S.
    Krzystolik, Magdalena G.
    Hawkins, Barbara S.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2019, (03):
  • [5] Economic Evaluation of Anti-Vascular Endothelial Growth Factor Therapy for Wet Age-Related Macular Degeneration
    Brown, Melissa M.
    Brown, Gary C.
    JAMA OPHTHALMOLOGY, 2020, 138 (01) : 48 - 49
  • [6] Effects of delay in anti-vascular endothelial growth factor intravitreal injections for neovascular age-related macular degeneration
    Joel Hanhart
    Rony Wiener
    Hashem Totah
    Evgeny Gelman
    Yishay Weill
    Adi Abulafia
    David Zadok
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, 260 : 1907 - 1914
  • [7] Effects of delay in anti-vascular endothelial growth factor intravitreal injections for neovascular age-related macular degeneration
    Hanhart, Joel
    Wiener, Rony
    Totah, Hashem
    Gelman, Evgeny
    Weill, Yishay
    Abulafia, Adi
    Zadok, David
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2022, 260 (06) : 1907 - 1914
  • [8] Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration
    Veloso, Carlos E.
    Kanadani, Tereza M.
    Pereira, Frederico B.
    Nehemy, Marcio B.
    OPHTHALMOLOGY, 2015, 122 (08) : 1569 - 1572
  • [9] Endophthalmitis Following Intravitreal Anti-Vascular Endothelial Growth Factor Injections for Neovascular Age-Related Macular Degeneration
    Moshfeghi, Andrew A.
    SEMINARS IN OPHTHALMOLOGY, 2011, 26 (03) : 139 - 148
  • [10] Anti-Vascular Endothelial Growth Factor (VEGF) Treatment of Age-Related Macular Degeneration
    Bolling, James P.
    CURRENT DRUG THERAPY, 2012, 7 (02) : 90 - 95